ASCO: Trametinib improves survival in metastatic melanoma

June 5, 2012
ASCO: trametinib improves survival in metastatic melanoma
For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF, treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free and overall survival, compared with chemotherapy, according to a study published online June 4 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free and overall survival, compared with chemotherapy, according to a study published online June 4 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Keith T. Flaherty, M.D., from the Massachusetts General Hospital Cancer Center in Boston, and colleagues conducted a phase 3 open-label trial involving 322 patients with with V600E or V600K mutations. Participants were randomly allocated in a 2:1 ratio to receive trametinib once daily (2 mg orally) or chemotherapy every three weeks (intravenous dacarbazine or paclitaxel). Crossover to trametinib was permitted for patients in the chemotherapy group who had disease progression.

The researchers found that the median progression-free survival was significantly higher in the trametinib group (4.8 versus 1.5 months; hazard ratio [HR] for disease progression or death, 0.45). Despite crossover, the overall survival rate at six months was 81 percent in the trametinib group and 67 percent in the chemotherapy group (HR for death, 0.54). The most common toxic effects in the trametinib group were rash, diarrhea, and peripheral edema, and these were managed by dose interruption and dose reduction.

"Trametinib, a MEK inhibitor, improved progression-free and overall survival, as compared with chemotherapy, in patients who had melanoma with a V600E or V600K BRAF mutation," the authors write. "Further work will be needed to determine the optimal role for trametinib in the treatment of metastatic melanoma."

The study was funded by GlaxoSmithKline, which manufactures trametinib; several authors disclosed to pharmaceutical companies, including GlaxoSmithKline.

Explore further: ASCO: Dabrafenib/Trametinib active in metastatic melanoma

More information: Abstract
Full Text
Editorial
More Information

Related Stories

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Research shows promising treatments against skin cancer

June 4, 2012
Two new experimental treatments against advanced melanoma have shown promise in keeping the deadly skin cancer at bay, according to research presented in the United States on Monday.

New drug, Vemurafenib, doubles survival of metastatic melanoma patients

March 1, 2012
A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib – increasing median survival ...

Response rate high for some patients with metastatic melanoma treated with vemurafenib

March 16, 2012
An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase ...

Vandetanib doesn't up survival in non-small-cell lung cancer

March 2, 2012
(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...

New melanoma drug Zelboraf nearly doubles survival in majority of patients

February 22, 2012
Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.